Johnson & Johnson (JNJ): Price and Financial Metrics

Johnson & Johnson (JNJ): $163.97

-0.10 (-0.06%)

POWR Rating

Component Grades














  • JNJ scores best on the Stability dimension, with a Stability rank ahead of 96.58% of US stocks.
  • JNJ's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • JNJ ranks lowest in Momentum; there it ranks in the 17th percentile.

JNJ Stock Summary

  • With a market capitalization of $429,029,575,266, JOHNSON & JOHNSON has a greater market value than 99.84% of US stocks.
  • JNJ's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 3,351.5 -- higher than 99.22% of US-listed equities with positive expected earnings growth.
  • The volatility of JOHNSON & JOHNSON's share price is greater than that of just 0.8% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to JNJ, based on their financial statements, market capitalization, and price volatility, are XOM, TSM, V, UNH, and WMT.
  • JNJ's SEC filings can be seen here. And to visit JOHNSON & JOHNSON's official web site, go to

JNJ Valuation Summary

  • JNJ's price/sales ratio is 4.5; this is 104.55% higher than that of the median Healthcare stock.
  • Over the past 243 months, JNJ's price/earnings ratio has gone down 5.3.

Below are key valuation metrics over time for JNJ.

Stock Date P/S P/B P/E EV/EBIT
JNJ 2022-09-01 4.5 5.7 23.7 22.2
JNJ 2022-08-31 4.4 5.6 23.1 21.7
JNJ 2022-08-30 4.5 5.6 23.3 21.9
JNJ 2022-08-29 4.5 5.6 23.3 21.9
JNJ 2022-08-26 4.5 5.7 23.5 22.1
JNJ 2022-08-25 4.6 5.8 23.9 22.5

JNJ Growth Metrics

    Its year over year cash and equivalents growth rate is now at -17.43%.
  • Its 5 year net cashflow from operations growth rate is now at 35.1%.
  • The 4 year net cashflow from operations growth rate now stands at 35.1%.
JNJ's revenue has moved up $11,374,000,000 over the prior 15 months.

The table below shows JNJ's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 95,588 23,582 18,366
2022-03-31 94,880 23,315 19,830
2021-12-31 93,775 23,410 20,878
2021-09-30 91,446 26,021 17,880
2021-06-30 89,190 26,114 17,767
2021-03-31 84,214 24,252 15,115

JNJ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • JNJ has a Quality Grade of B, ranking ahead of 92.45% of graded US stocks.
  • JNJ's asset turnover comes in at 0.52 -- ranking 78th of 682 Pharmaceutical Products stocks.
  • CBIO, CLSD, and ABBV are the stocks whose asset turnover ratios are most correlated with JNJ.

The table below shows JNJ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-10-03 0.520 0.675 0.295
2021-07-04 0.514 0.670 0.302
2021-04-04 0.498 0.662 0.273
2021-01-03 0.501 0.656 0.272
2020-09-27 0.504 0.657 0.332
2020-06-28 0.514 0.657 0.307

JNJ Price Target

For more insight on analysts targets of JNJ, see our JNJ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $187.95 Average Broker Recommendation 1.53 (Moderate Buy)

JNJ Stock Price Chart Interactive Chart >

Price chart for JNJ

JNJ Price/Volume Stats

Current price $163.97 52-week high $186.69
Prev. close $164.07 52-week low $155.72
Day low $163.08 Volume 780,106
Day high $164.02 Avg. volume 7,404,706
50-day MA $170.81 Dividend yield 2.75%
200-day MA $172.06 Market Cap 431.11B

Johnson & Johnson (JNJ) Company Bio

Founded in 1886, Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture, and sale of products in the healthcare field within its Consumer, Pharmaceutical and Medical Devices segments. The Consumer segment consists of skin and self-care product brand names such as Aveeno, Neutrogena, Rogaine, Tylenol, Motrin, Listerine, and Band-Aid. Johnson’s Pharmaceutical segment contains biopharma products that address immune, cardiovascular, metabolic, and infectious disease medical conditions. The Medical Device segment develops products centered around orthopedic, surgical, intervention, and vision solutions. The company has over 130,000 employees worldwide and is headquartered in New Brunswick, New Jersey. The company’s current Chief Executive Officer is Alex Gorsky.

JNJ Latest News Stream

Event/Time News Detail
Loading, please wait...

JNJ Latest Social Stream

Loading social stream, please wait...

View Full JNJ Social Stream

Latest JNJ News From Around the Web

Below are the latest news stories about JOHNSON & JOHNSON that investors may wish to consider to help them evaluate JNJ as an investment opportunity.

3 Great Dividend Stocks to Buy in September

Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie boasts practically all the characteristics of an outstanding dividend stock, including a stable business with increasing revenue and earnings, solid growth avenues, a juicy yield, a conservative payout ratio, and of course, an impressive history of dividend hikes.

Yahoo | September 3, 2022

Long-Term Analyst: Don’t Play the “Fool’s Game” of Timing the Market and Buy These 10 Stocks

In this article, we will discuss some of the best stocks to buy according to Dave Smith, Chief Investment Officer at investment management company Rockland Trust. If you want to explore similar stocks, you can also look at Long-Term Analyst: Buy These 5 Stocks. David Smith has been in the financial services industry for over […]

Yahoo | September 2, 2022

Fate Therapeutics (FATE) Down 17% Since Last Earnings Report: Can It Rebound?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 2, 2022

“A Strong Power in Rapid Ascent”: 10 China Stocks in Ray Dalio’s Portfolio

In this article, we discuss 10 China stocks in Ray Dalio’s portfolio. If you want to skip our analysis of Dalio’s stance on China, go directly to 5 China Stocks in Ray Dalio’s Portfolio. Ray Dalio, the billionaire chief of Bridgewater Associates, shared his thoughts on China in a series of tweets on August 31. […]

Yahoo | September 2, 2022

Johnson & Johnson To Settle New Hampshire Opioid Lawsuit With Payment Of $40.5M: Report

Reuters reported that Johnson & Johnson (NYSE: JNJ) would pay $40.5 million to settle 2018 New Hampshire's claims about the U.S. opioid epidemic, averting a trial scheduled to begin next week. New Hampshire accused JNJ and its unit Janssen Pharmaceuticals of aggressively marketing opioids to doctors and patients, misrepresenting their addictive properties. "This resolution provides a positive step forward in ensuring these devastating business practices are not repeated," Governor Chris Sununu s

Yahoo | September 2, 2022

Read More 'JNJ' Stories Here

JNJ Price Returns

1-mo -3.00%
3-mo -4.33%
6-mo -1.90%
1-year -2.10%
3-year 39.66%
5-year 42.83%
YTD -2.26%
2021 11.44%
2020 10.82%
2019 16.22%
2018 -5.13%
2017 24.43%

JNJ Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full JNJ Dividend History

Continue Researching JNJ

Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:

Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8427 seconds.